For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
To read the full story
Related Article
- Japan Health Ministry Panel Gives Blessing to Novartis’ PNH Drug Iptacopan and More
June 4, 2024
- Tapinarof Cream Hits Main Goal in PIII Eczema Trial in Children: JT/Torii
June 3, 2024
- Novartis’ Fabhalta, Novo’s Awiqli, and More Up for PAFSC Review on May 31
May 20, 2024
- JT’s Tapinarof Cream Safe and Effective for Eczema: Japan PIII Study
July 21, 2022
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
BUSINESS
- UCB to End Cimzia Partnership with Astellas in Japan
November 7, 2024
- Chugai to Discontinue Sale of Rocaltrol in Japan
November 7, 2024
- Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
- Fujifilm CDMO Unit’s New Bioreactors Now Up and Running in Denmark
November 6, 2024
- Eisai and Taiho VC Firms Certified for AMED Startup Project
November 6, 2024
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…